India’s Strides Arcolab, Eli Lilly in general cancer drug tie-up

Wed Dec 5, 2012 5:38am EST

MUMBAI (Reuters) – India’s Strides Arcolab and Eli Lilly will jointly make and discharge general cancer drugs for building markets, a drugmakers pronounced on Wednesday, as a U.S. association looks to enhance a participation in rising markets.

The tie-up is a latest in a line of agreements between ‘Big Pharma’ companies eyeing larger entrance to high-growth rising markets, and Indian companies looking for tellurian expertise.

Under a agreement, Strides auxiliary Agila Specialties will make a general verbal and injectable cancer drugs that Lilly will register and market.

The companies will start with 10 medicines, with an choice for Lilly to boost a series in a future.

Annual drug spending in rising markets is approaching to grow 12 to 15 percent from 2012 to 2016, according to medical information provider IMS Health, and is on lane to make adult 28 percent of tellurian sales by 2015, adult from 12 percent in 2005.

“Cancer medicines of a top peculiarity continue to be an unmet need in many markets around a world,” Jacques Tapiero, Lilly, comparison vice-president, pronounced in a statement.

(Reporting by Henry Foy; Editing by Prateek Chatterjee)

Source: Health Medicine Network